ÖZET
Amaç:
Tanı anında akciğer kanserlerinin %25-30’u erken evre küçük hücreli dışı akciğer kanseridir (KHDAK). Yaşlı hastalar klinik çalışmalarda yeteri kadar temsil edilmemişlerdir. Bu çalışmada 65 yaş üstü erken evre KHDAK’li hastalarda adjuvan kemoterapi sonuçlarını araştırdık.
Yöntemler:
Türkiye’de iki ayrı merkezde 111 yaşlı erken evre KHDAK’li hastanın kayıtları retrospektif olarak incelendi. Toplanan kayıtlar demografik özellikleri, klinik değerlendirmeleri ve tedavi sonuçları ile bilgileri içermekte idi. Sağkalım Kaplan-Meier metodu ile ve prognostik faktörler log-rank ve Cox regresyon testleri ile değerlendirildi.
Bulgular:
Medyan hastalıksız sağkalım 22,6 ay idi. Tek değişkenli analizlerde, hastalıksız sağkalım ile evre, performans skoru (PS), adjuvan kemoterapi arasında anlamlı ilişki mevcuttu (p<0,05). Genel sağkalım ile evre, PS ve adjuvan kemoterapi arasında anlamlı ilişki bulundu (p<0,05). Tüm grup için genel sağkalım 41,6 ay idi. Çok değişkenli analizlerde evre, PS ve adjuvan kemoterapi ile genel sağkalım ve hastalıksız sağkalım arasında anlamlı ilişki saptandı (p<0,05).
Sonuç:
Yaşlı erken evre KHDAK’li hastaların sağkalımını evre, PS ve adjuvan kemoterapi etkilemektedir. Tedavi planına karar verilirken sadece yaşın değil bu faktörlerin de değerlendirilmesi gerekir.
References
1
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2
T.C Ministry of Health. Turkey Cancer Statistics, 2016. Available from: http://kanser.gov.tr/ Dosya/ca_ istatistik/ANA_rapor_2013v01_2.pdf. Accessed: 22.05.2017.
3
Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 2009;3:215-24.
4
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-65.
5
Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010;21:692-706.
6
Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: A review of the evidence. Chest 2005;128:947-57.
7
Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000;36:1741-54.
8
Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-77.
9
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
10
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
11
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
12
Kefeli U, Kaya S, Ustaalioglu BO, Bilici A, Kefeli AU, Yildirim ME, et al. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience. Med Oncol 2010;28:661-6.
13
Cuffe S, Booth CM, Peng Y, Darling GE, Li G, Kong W, et al. Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol 2012;30:1813-21.
14
Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingston RB, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007;25:1553-61.
15
Früh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008;26:3573-81.
16
Ganti AK, Williams CD, Gajra A, Kelley MJ. Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. Cancer 2015;121:2578-85.
17
Wisnivesky JP, Smith CB, Packer S, Strauss GM, Lurslurchachai L, Federman A, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011;343:d4013.
18
American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and statistics/ annual-cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf. Accessed: 2.05.2017.
19
Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000;343:1627-33.
20
Harpole DH Jr, Herndon JE II, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
21
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Bethesda, MD: National Cancer Institute; 2014. Available from: http://seer.cancer.gov/csr/1975_2011/ Accessed: 08.07.2015.
22
Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I non small cell lung cancer patients: a population based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007;110:1532-41.
23
Demirci NY, Ulger S, Yilmaz U, Aydogdu K, Yilmaz A, Erdogan Y. Radical Oncological Surgery and Adjuvan Therapy in Non- Small Cell Lung Cancer Patients over 70 years of Age. Asian Pac J Cancer Prev 2015;16:4711-14.
24
Inal A, Kaplan MA, Kucukoner M, Karakus A, Isikdogan A. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: A retrospective analysis of single institution. J BUON 2012;17:533-6.
25
Unal D, Oguz A, Goksu SS, Tasdemir A, Kurtul N, Eroglu C, et al. Effect of prognostic factors on survival in elderly patients with non-small cell lung cancer. Turkish Journal of Geriatrics 2014;17:113-8.
26
Bunn PA Jr, Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2003;95:341-3.
27
Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013;5:3-29.
